Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Partnering

Immunovia’s vision is to lead the way in bioinformatic-assisted diagnostics towards a future where all patients are diagnosed in time for effective treatment, better quality of life and significantly improved survival.

Our focus is to develop best in class diagnostics tests for early detection using state of the art technologies, including Immunovia’s proprietary protein microarray platform IMMray™.

Protein Microarrays

Immunovia’s proprietary platform, IMMray™, uses a small volume of blood to measure proteins in a highly multiplexed fashion. IMMray™ microarrays are based on recombinant antibodies from Immunovia´s proprietary antibody library.

IMMray technology platform

Production

Immunovia headquarters in Lund houses a state of the art facility for producing antibodies and printing microarrays for proteomics analysis using robotic systems and high-throughput processes.

Quality

Immunovia’s quality systems will meet the regulatory requirements for ISO 13485 and 15189.

Laboratories

Immunovia plans to deploy patient testing from accredited laboratories. Read more about our Immunovia Dx Laboratory, Lund and Immunovia Inc, Marlborough.

Partnering

Healthcare Systems

If you are interested in partnering with us on our clinical trials or other joint offerings for your patients, please reach out at partners@immunovia.com.

Other Partners

We are interested in innovative research opportunities and collaborations that could impact early detection and early stage cancer. If you would like to work with us, please reach out at partners@immunovia.com.